Consensus CureVac N.V.

Equities

CVAC

NL0015436031

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
3.89 ^USD	+3.18%		+5.42%	-7.60%

May. 28	CureVac, GSK Begin Dosing in Phase 2 Study for Seasonal Influenza Vaccine Candidate	MT
May. 28	CureVac N.V. Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK	CI

Evolution of the average Target Price on CureVac N.V.

Price target over the last 5 years

History of analyst recommendation changes

e8ba2c6373b057f9ca65af42e7.WYICh4yTDqFvqNqStFrFVaxGEmZj_zNU4p-m_03bfeA.NLNoycC-Zpks_a2n_SKOAeAWRTElj3ks0drwtBeVOYo6r0DSzt5X2SvwrQ~50c424ecaa8ccc99ce4898f602e1d1ba

Analyst Recommendations on CureVac N.V.

CUREVAC : Significant cash drain in the Q1	May. 23
CUREVAC : A missed opportunity	May. 02
UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating	Apr. 26	MT
Leerink Partners Downgrades CureVac to Market Perform From Outperform, Sets Price Target at $4	Apr. 25	MT
Kempen Upgrades CureVac to Buy From Neutral, Price Target is $10	Dec. 22	MT
CUREVAC : An untrimmed pipeline becomes costly	Nov. 29
CUREVAC : Unchanged cash drain	Nov. 28
CUREVAC : A missed opportunity	23-08-21
CUREVAC : Higher losses expected in future	23-07-25
CUREVAC : Some glimpse of positive pipeline developments	23-06-21
SVB Securities Initiates CureVac at Outperform With $13 Price Target	23-06-08	MT
CUREVAC : Runway prolonged	23-05-30
CUREVAC : One big point despite many misses	23-05-02
JMP Securities Adjusts Price Target on CureVac to $24 From $34, Maintains Outperform Rating	23-04-26	MT
CUREVAC : Everything hangs on the decision of the new CEO	23-03-16
UBS Upgrades CureVac to Buy From Neutral, Adjusts Price Target to $18 From $8	23-01-19	MT
CUREVAC : UBS raises its recommendation to Buy	23-01-19	ZD
Health Care Down Sharply on Rate-Sensitive Sector Bias -- Health Care Roundup	23-01-09	DJ
Jefferies Upgrades CureVac to Buy From Hold	23-01-09	MT
CUREVAC : Berenberg reaffirms its Buy rating	23-01-06	ZD
UBS Initiates Coverage on CureVac With Neutral Rating, $8 Price Target	22-12-20	MT
JMP Securities Adjusts Price Target on CureVac to $34 From $37, Maintains Market Outperform Rating	22-11-17	MT
Berenberg Bank Adjusts CureVac Price Target to $22 From $45, Maintains Buy Rating	22-11-17	MT
Roche’s Alzheimer’s failure has sector-wide implications	22-11-14
Berenberg US CEO Conference	22-11-01	FA

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.587 EUR

Average target price

8.728 EUR

Spread / Average Target

+143.32%

High Price Target

16.61 EUR

Spread / Highest target

+363.12%

Low Price Target

2.391 EUR

Spread / Lowest Target

-33.34%

Consensus detail

Consensus revision (last 18 months)

Analysts covering CureVac N.V.

alphavalue	Martin Schnee
UBS
Leerink Partners
Kempen
SVB Securities LLC
JMP Securities
Jefferies & Co.
BERENBERG	Zhiqiang Shu
Berenberg Bank
BofA Securities
Deutsche Bank Securities
Guggenheim

Ratings for CureVac N.V.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar